Ultragenyx Pharmaceutical Inc at Piper Sandler Healthcare Conference Transcript
Okay. We're going to go ahead and get started. Thanks, everybody, for being here, and thanks for attending. This is the 34th Annual Piper Sandler Healthcare Conference. My name is Chris Raymond. I'm one of the lead -- Biotech leads here on the research side at Piper. Very pleased to have with us Emil Kakkis who is the CEO -- President and CEO of Ultragenyx. Just to go over the format here, this is a fireside chat format, so very informal. So if anybody has any questions from the audience, please raise your hand, I'd love to get some participation in here for you guys. I have probably 3 hours of questions for Emil, but we only have about 20 minutes. So we're going to try to pack as much as we can in here.
But before we do that, Emil, maybe just provide for folks who might not -- for the rare investor who doesn't know Ultragenyx, maybe just give us a sort of a 2- to 3-minute overview of the company and then we'll jump in.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |